Final NICE green light for Pfizer’s Mylotarg

15th November 2018 Uncategorised 0

Cost regulators for the NHS in England and Wales have now published final guidelines recommending Mylotarg, alongside daunorubicin and cytarabine, as an option for untreated de novo CD33-positive acute myeloid leukaemia (AML).

More: Final NICE green light for Pfizer’s Mylotarg
Source: News